Construction and test of a cosmic ray telescope based on CMS Drift Tube chambers and data acquisition prototypes of the Phase-2 upgrade

In this thesis work, a cosmic-ray telescope was set up in the INFN laboratories in Bologna using smaller size replicas of CMS Drift Tubes chambers, called MiniDTs, to test and develop new electronics for the CMS Phase-2 upgrade. The MiniDTs were assembled in INFN National Laboratory in Legnaro, Italy. Scintillator tiles complete the telescope, providing a signal independent of the MiniDTs for offline analysis. The telescope readout is a test system for the CMS Phase-2 upgrade data acquisition design. The readout is based on the early prototype of a radiation-hard FPGA-based board developed for the High Luminosity LHC CMS upgrade, called On Board electronics for Drift Tubes. Once the set-up was operational, we developed an online monitor to display in real-time the most important observables to check the quality of the data acquisition. We performed an offline analysis of the collected data using a custom version of CMS software tools, which allowed us to estimate the time pedestal and drift velocity in each chamber, evaluate the efficiency of the different DT cells, and measure the space and time resolution of the telescope system.

Measurement of the top quark mass in multijet events with the CMS experiment at LHC

La massa del quark top è qui misurata per mezzo dei dati raccolti dall’esperimento CMS in collisioni protone-protone ad LHC, con energia nel centro di massa pari ad 8 TeV. Il campione di dati raccolto corrisponde ad una luminosità integrata pari a 18.2 /fb. La misura è effettuata su eventi con un numero di jet almeno pari a 6, di cui almeno due b-taggati (ovvero identificati come prodotto dell’adronizzazione di due quark bottom). Il valore di massa trovato è di (173.95 +- 0.43 (stat)) GeV/c2, in accordo con la media mondiale. The top quark mass is here measured by using the data that have been collected with the CMS experiment in proton-proton collisions at the LHC, at a center-of-mass energy of 8 TeV. The dataset which was used, corresponds to an integrated luminosiy of 18.2 /fb. The mass measurement is carried out by using events characterized by six or more jets, two of which identified as being originated by the hadronization of bottom quarks. The result of the measurement of the top quark mass performed here is: (173.95 +- 0.43 (stat)) GeV/c2, in accordance with the recently published world average.

Singlet extensions of the standard model at LHC Run 2: benchmarks and comparison with the NMSSM

The Complex singlet extension of the Standard Model (CxSM) is the simplest extension that provides scenarios for Higgs pair production with different masses. The model has two interesting phases: the dark matter phase, with a Standard Model-like Higgs boson, a new scalar and a dark matter candidate; and the broken phase, with all three neutral scalars mixing. In the latter phase Higgs decays into a pair of two different Higgs bosons are possible. In this study we analyse Higgs-to-Higgs decays in the framework of singlet extensions of the Standard Model (SM), with focus on the CxSM. After demonstrating that scenarios with large rates for such chain decays are possible we perform a comparison between the NMSSM and the CxSM. We find that, based on Higgs-to-Higgs decays, the only possibility to distinguish the two models at the LHC run 2 is through final states with two different scalars. This conclusion builds a strong case for searches for final states with two different scalars at the LHC run 2. Finally, we propose a set of benchmark points for the real and complex singlet extensions to be tested at the LHC run 2. They have been chosen such that the discovery prospects of the involved scalars are maximised and they fulfil the dark matter constraints. Furthermore, for some of the points the theory is stable up to high energy scales. For the computation of the decay widths and branching ratios we developed the Fortran code sHDECAY, which is based on the implementation of the real and complex singlet extensions of the SM in HDECAY.

Search for heavy neutrinos in $D_s$ decays with the CMS detector at LHC

This thesis presents a search for a sterile right-handed neutrino $N$ produced in $D_s$ meson decays, using proton-proton collisions collected by the CMS experiment at the LHC. The data set used for the analysis, the B-Parking data set, corresponds to an integrated luminosity of $41.7\,\textrm{fb}^{-1}$ and was collected during the 2018 data-taking period. The analysis is targeting the $D_s^+\rightarrow N(\rightarrow\mu^{\pm}\pi^{\mp})\mu^{+}$ decays, where the final state muons can have the same electric charge allowing for a lepton flavor violating decay. To separate signal from background, a cut-based analysis is optimized using requirements on the sterile neutrino vertex displacement, muon and pion impact parameter, and impact parameter significance. The expected limit on the active-sterile neutrino mixing matrix parameter $|V_{\mu}|^2$ is extracted by performing a fit of the $\mu\pi$ invariant mass spectrum for two sterile neutrino mass hypotheses, 1.0 and 1.5 GeV. The analysis is currently blinded, following the internal CMS review process. The expected limit ranges between approximately $10^{-4}$ for a 1.0 GeV neutrino to $7\times10^{-5}$ for a 1.5 GeV neutrino. This is competitive with the best existing results from collider experiments over the same mass range.

Undoubtable signs of CP-violation in Higgs decays at the LHC run 2

With the discovery of the Higgs boson at the Large Hadron Collider the high energy physics community's attention has now turned to understanding the properties of the Higgs boson, together with the hope of finding more scalars during run 2. In this work we discuss scenarios where using a combination of three decays, involving the 125 GeV Higgs boson, the Z boson and at least one more scalar, an indisputable signal of CP-violation arises. We use a complex two-Higgs doublet model as a reference model and present some benchmark points that have passed all current experimental and theoretical constraints, and that have cross sections large enough to be probed during run 2.

Design, implementation, and performance of a distributed and scalable sensor system for critical distance measurements in the CMS detector at LHC

The “CMS Safety Closing Sensors System” (SCSS, or CSS for brevity) is a remote monitoring system design to control safety clearance and tight mechanical movements of parts of the CMS detector, especially during CMS assembly phases. We present the different systems that makes SCSS: its sensor technologies, the readout system, the data acquisition and control software. We also report on calibration and installation details, which determine the resolution and limits of the system. We present as well our experience from the operation of the system and the analysis of the data collected since 2008. Special emphasis is given to study positioning reproducibility during detector assembly and understanding how the magnetic fields influence the detector structure.

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

BACKGROUND: Cilengitide is a selective integrin inhibitor that is well tolerated and has demonstrated biologic activity in patients with recurrent malignant glioma. The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing. METHODS: In total, 112 patients were accrued. Eighteen patients received standard radiation and temozolomide with cilengitide in a safety run-in phase followed by a randomized phase 2 trial with 94 patients assigned to either a 500 mg dose group or 2000 mg dose group. The trial was designed to estimate overall survival benefit compared with a New Approaches to Brain Tumor Therapy (NABTT) Consortium internal historic control and data from the published European Organization for Research and Treatment of Cancer (EORTC) trial EORTC 26981. RESULTS: Cilengitide at all doses studied was well tolerated with radiation and temozolomide. The median survival was 19.7 months for all patients, 17.4 months for the patients in the 500 mg dose group, 20.8 months for patients in the 2000 mg dose group, 30 months for patients who had methylated O6-methylguanine-DNA methyltransferase (MGMT) status, and 17.4 months for patients who had unmethylated MGMT status. For patients aged ≤70 years, the median survival and survival at 24 months was superior to what was observed in the EORTC trial (20.7 months vs 14.6 months and 41% vs 27%, respectively; P = .008). CONCLUSIONS: Cilengitide was well tolerated when combined with standard chemoradiation and may improve survival for patients newly diagnosed with glioblastoma multiforme regardless of MGMT methylation status. The authors concluded that, from an efficacy and safety standpoint, future trials of this agent in this population should use the 2000 mg dose. Cancer 2012. © 2012 American Cancer Society.

IPH response to Phase 2 of the New Strategic Direction for Alcohol and Drugs 2011-2016 (Northern Ireland)

The IPH response to the New Strategic Direction for Alcohol and Drugs questionnaire which has been designed to help stakeholders respond to New Strategic Direction for Alcohol and Drugs Phase 2 (2011-2016) consultation document.

New Strategic Direction for Alcohol & Drugs Phase 2 Second Update Report (June 2014) (PDF 1MB)

This second annual report provides an update of progress against the outcomes and indicators set out in NSD Phase 2.

New Strategic Direction for Alcohol and Drugs Phase 2 Update Report (March 2013) (PDF 652KB)

Update Report on NSD for Alcohol and Drugs Phase 2 - March 2013

New Strategic Direction for Alcohol and Drugs Phase 2 (2011-2016) - (December 2011) (PDF 886 KB)

New Strategic Direction for Alcohol and Drugs Phase 2 (2011-2016) - A framework for Reducing Alcohol and Drug Related Harm in Northern Ireland (December 2011)

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Extranodal NK/T-cell lymphoma, nasal type, is a rare and highly aggressive disease with a grim prognosis. No therapeutic strategy is currently identified in relapsing patients. We report the results of a French prospective phase II trial of an L-asparaginase-containing regimen in 19 patients with relapsed or refractory disease treated in 13 centers. Eleven patients were in relapse and 8 patients were refractory to their first line of treatment. L-Asparaginase-based treatment yielded objective responses in 14 of the 18 evaluable patients after 3 cycles. Eleven patients entered complete remission (61%), and only 4 of them relapsed. The median overall survival time was 1 year, with a median response duration of 12 months. The main adverse events were hepatitis, cytopenia, and allergy. The absence of antiasparaginase antibodies and the disappearance of Epstein-Barr virus serum DNA were significantly associated with a better outcome. These data confirm the excellent activity of L-asparaginase-containing regimens in extranodal NK/T-cell lymphoma. L-Asparaginase-based treatment should thus be considered for salvage therapy, especially in patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma warrants evaluation in prospective trials. This trial is registered at www.clinicaltrials.gov as #NCT00283985.

Phase 2 Parent/Carer Questionnaire: Review of Allied Health Professions��' (AHP) support for children/young people with a statement of special educational needs

We want to know what you think about the AHP services for your child. We will also seek views of AHPs and teachers who work with your children and we will use them all to inform our decisions. This phase of the review is focusing on current AHP services for children/young people with a statement of special educational needs enrolled in mainstream schools and learning support centres/units attached to a mainstream school.

Review of AHP Support for Children with Statements of Special Educational Needs in Special Schools and Mainstream Education: Phase 2 Engagement Plan

This engagement plan outlines the collaborative and partnership approach with key stakeholders in the second phase of the Review of AHP Support for Children with Statements of Special Educational Needs in Special Schools and Mainstream Education. It provides detail on how communication objectives will be met. It gives information on: Stakeholder Analysis for Phase Two of the Review Membership of the Project Board Membership of the Professional Stakeholder Reference Group